No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.

MAKE XIIDRA
YOUR FIIRST
CHOICE

When artificial tears aren’t enough, consider prescribing
Xiidra for symptomatic Dry Eye patients1,2

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

GET READY FOR IMPROVEMENT

Xiidra is the only eye drop approved to treat both the signs and symptoms of Dry Eye Disease.2-4 Xiidra improved patient-reported symptoms of eye dryness and signs of inferior corneal staining in clinical trials.2 Think about Xiidra for symptomatic Dry Eye patients.2

Four randomized, double-masked, 12-week trials evaluated the efficacy and safety of Xiidra versus vehicle as assessed by improvement in the signs (measured by Inferior Corneal Staining Score) and symptoms (measured by Eye Dryness Score) of Dry Eye Disease (N=2133).2



Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.

References

  1. DEWS Research Subcommittee. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):179-193.
  2. Xiidra [Prescribing Information]. Lexington, MA: Shire US.
  3. Food and Drug Administration, Center for Drug Evaluation and Research. Xiidra NDA 208073 approval letter, July 11, 2016.
  4. Food and Drug Administration. Electronic Orange Book. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Accessed April 1, 2016.